Methotrexate for psoriasis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  da Silva, Carolina A P ^a   Von Kossel, Karen ^a   Leszczynski, Marcos ^a   Melnik, Tamara ^a   Riera, Rachel ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Cochrane Center   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADVERSE EVENT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMA; HUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85034025779     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010498     Document Type: Article

References (14)

1. Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al.Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Journal of the European Academy of Dermatology & Venereology 2011;25(7):758-64. [PUBMED: 21198946].
2. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd Edition. Vol. 1, Mosby, 2008.
3. Carretero G, Puig L, Dehesa L, Carrscosa JM, Ribera M, Sánches-Regaña M, et al.Guidelines on the use of methotrexate in psoriasis [Metotrexato: Guia de uso en psoriasis]. Actas Dermo-Sifiliograficas 2010;101(7):600-13.
4. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. Interventions for guttate psoriasis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001213].
5. Chalmers R, Griffiths CEM, O'Sullivan T. Interventions for chronic palmoplantar pustular psoriasis. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001433.pub2].
6. Elbourne DR, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
7. Fairhurst DA, Ashcroft DM, Griffiths CEM. Optimal management of severe plaque form of psoriasis. American Journal of Clinical Dermatology 2005;6(5):283-94.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD000212].
11. Krueger G, Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment.. Journal of the American Academy of Dermatology 2005;53(1 Suppl 1):S94-100.
12. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al.Guidelines of care for management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Journal of the American Academy of Dermatology 2009;61(3):451-85.
13. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criteron to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-9.
14. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick's Dermatology in General Medicine. 7th Edition. New York: McGraw-Hill Professional, 2007. [978-0071466905].